represented and suggested that the article would be effective in the treatment of disturbances of the mammary system of dairy cattle; that it would be effective to build up resistance of the animals to prevent any disturbance of the mammary system; and that the *Flex-O Udder Ointment* would be effective to assist the healthy milk secretion and flow of blood to the udder.

*Flex-O Udder Ointment.* Misbranding, Section 502 (a), certain label statements were false and misleading since they represented and suggested that the article would be effective in the treatment of disease conditions of the udder of cows.

*Flex-O Scourene.* Misbranding, Section 502 (a), the designation "Scourene" and certain label statements were false and misleading since they represented and suggested that the article would be effective for the disease condition of animals known as scours; that it would be effective as an astringent medication for intestinal derangements of farm and dairy animals; that it would be effective for intestinal infections in farm animals; that it would be effective as an astringent; and that it would be effective in the treatment of simple scours in calves, colts, pigs, dogs, and lambs, or where such contagion exists among fowls.

The articles would not be effective for the purposes claimed.

DISPOSITION: January 21, 1947. No claimant having appeared, judgment of forfeiture was entered and the product was ordered destroyed.

## DRUGS ACTIONABLE BECAUSE OF OMISSION OF, OR UNSATISFACTORY, INGREDIENTS STATEMENTS*

**1999. Misbranding of estrogenic substance powder and estrogenic substance in sesame oil. U. S. v. 1 Bottle of Estrogenic Substance Powder (and 2 seizure actions against Estrogenic Substance in Sesame Oil). Consent decrees of condemnation. Products ordered released under bond to be relabeled.** (F. D. C. Nos. 16265, 16288, 16289. Sample Nos. 3846–H, 3847–H, 4085–H, 31328–H.)

LIBELS FILED: Between May 23 and 31, 1945, Southern District of California and Eastern District of Pennsylvania.

ALLEGED SHIPMENT: On or about March 27 and April 10, 1945, by the Hormorgano Corporation, from Jamaica, N. Y.

PRODUCT: 1 bottle of *estrogenic substance powder* at Pasadena, Calif., and 10 bottles of *estrogenic substance in sesame oil* at Philadelphia. Pa. Examination showed that the *estrogenic substance powder* contained 20 percent of estrogenic or other phenolic compounds and 80 percent of a diluent. The estrogenic potency was due principally to estradiol. Examination of the *estrogenic substance in sesame oil* showed that the product was an oil solution containing principally estradiol, with perhaps a small proportion of estrone or other ketosteroids.

LABEL, IN PART: "Estrogenic Substance in Sesame Oil," or "Estrogenic Substance Powder."

NATURE OF CHARGE: Misbranding, Section 502 (e), the products were fabricated from two or more ingredients and the labels failed to bear the common or usual name of each active ingredient, since the label designation "Estrogenic Substance" is not the specific name of any particular substance, but is a generic name for a class of substances.

DISPOSITION: June 19 and September 7, 1945. The Hormorgano Corporation, claimant, having consented to the entry of decrees, and the Philadelphia cases having been consolidated, judgments of condemnation were entered and the products were ordered released under bond to be relabeled under the supervision of the Food and Drug Administration.

**2000. Misbranding of estrogenic substance. U. S. v. 1 Bottle of Estrogenic Substance. Consent decree of condemnation. Product ordered released under bond.** (F. D. C. No. 19581. Sample No. 45051–H.)

LIBEL FILED: April 1, 1946, Southern District of California.

ALLEGED SHIPMENT: On or about March 1, 1946, by the Tremond Co., from Brooklyn, N. Y.

PRODUCT: 1 bottle of *estrogenic substance* at Los Angeles, Calif.

NATURE OF CHARGE: Misbranding, Section 502 (e) (2), the article was fabricated from two or more ingredients and its label failed to bear the common or

*See also Nos. 1955, 1956, 1961, 1962, 1966, 1978, 1997.

usual name of each active ingredient, since the label designation "Estrogenic Substance" is not the specific name of any particular substance, but is a generic name for a class of substances.

DISPOSITION: July 16, 1946. The Tremond Co., New York, N. Y., claimant, having consented to the entry of a decree, judgment of condemnation was entered and the product was ordered released under bond for relabeling under the supervision of the Federal Security Agency.

## INDEX TO NOTICES OF JUDGMENT D. D. N. J. NOS. 1951 TO 2000

### PRODUCTS



[1] (1981) Permanent injunction issued.
[2] (1980) Permanent injunction issued. Contains opinions of the court, findings of fact, and conclusions of law.

# FEDERAL SECURITY AGENCY

FOOD AND DRUG ADMINISTRATION

# NOTICES OF JUDGMENT UNDER THE FEDERAL FOOD, DRUG, AND COSMETIC ACT

[Given pursuant to section 705 of the Food, Drug, and Cosmetic Act]

2001–2050

DRUGS AND DEVICES

The cases reported herewith were instituted in the United States district courts by the United States attorneys acting upon reports submitted by direction of the Federal Security Administrator.

MAURICE COLLINS, *Acting Administrator, Federal Security Agency.*

WASHINGTON, D. C., *June 5, 1947.*

CONTENTS*



## DRUG ACTIONABLE BECAUSE OF POTENTIAL DANGER WHEN USED ACCORDING TO DIRECTIONS

**2001. Misbranding of Anademin Tablets. U. S. v. 52 Packages and 5 Packages of Anademin Tablets. Default decree of condemnation and destruction.** (F. D. C. No. 20102. Sample No. 14079–H.)

LIBEL FILED: June 26, 1946, Southern District of Ohio.

ALLEGED SHIPMENT: On or about October 30, 1945, and April 8 and May 29, 1946, by the Anademin Chemical Co., from Chattanooga, Tenn.

PRODUCT: 52 100-tablet packages and 5 500-tablet packages of *Anademin Tablets* at Cincinnati, Ohio. Assay by the method described in the Twelfth Revision of the United States Pharmacopoeia showed that each tablet of the product had a potency of 3.17 U. S. P. Digitalis Units.

LABEL, IN PART: "100 [or "500"] 5 grain Tablets Anademin * * * Caution: To be used only by or on the prescription of a physician. Assay: As assayed by the method described in U. S. P. XII for Digitalis, each tablet has a potency of 1.25 U. S. P. Digitalis units."

*For omission of, or unsatisfactory, ingredients statements, see Nos. 2003, 2005, 2008, 2031, 2034, 2035, 2046; failure to comply with the packaging requirements of an official compendium, No. 2028; failure to bear a label containing the name and place of business of the manufacturer, packer, or distributor, Nos. 2003, 2028.